LENOVO
31.7.2024 15:01:34 CEST | Business Wire | Press release
Today, Lenovo has joined forces with Databricks to drive AI adoption amongst its customers. As a Databricks Consulting & Systems Integration (C&SI) Select Tier Partner, Lenovo will work with businesses to help them take advantage of enhanced data management capabilities, streamlining access to data from multiple sources and removing barriers to successful AI usage.
The offering will run through the Lenovo AI Center of Excellence (AI CoE), designed to help customers put AI to work for their organizations quickly, cost-effectively and at scale, with solutions that bring AI from ideation to reality. Working with the Databricks Data Intelligence Platform, Lenovo will help businesses to bring their data sources together, allowing them to increase the use of generative AI, improve their data analytics capabilities and drive innovation. The Lenovo AI Center of Excellence (AI CoE) will provide services to help customers define outcomes and rapidly innovate with the Databricks Platform to meet the unique needs of their organization.
“We’ve spoken to many customers at various stages of their AI journeys and, while most want to reap the benefits and feel the urgency to do so, their organizations aren’t ready,” commented Linda Yao, Chief Operating Officer and Head of Strategy, Lenovo Solutions & Services Group. “Our latest study showed that 90% of the CIOs we surveyed see AI as a game changer, yet over half feel their organizations lack the technical skills to scale AI quickly. By adding Databricks to Lenovo's ecosystem of leading software vendors, we can further enable our AI for all vision and bring the technology to a broader set of customers."
Starting in the Greater China and Asia Pacific Region, then rolling out globally, Lenovo will offer end-to-end expertise in solutions and services for data management, including cloud, data and AI strategy, data platform modernization, data migration, pre-built code for quick implementation, optimization, governance and audit management, and AI and ML use cases.
"Our partnership with Lenovo showcases our unwavering commitment to democratize data and AI for all organizations. We are proud to see our relationship with Lenovo transform from customer to key partner. Together, we are driving unprecedented innovation, accelerating growth, and delivering exceptional value to our customers on the Databricks Data Intelligence Platform," said Greg Taylor, VP of Partners, Databricks.
Lenovo was awarded partner status due to its broad and deep expertise in IT solutions, including over 10 years of public cloud solutions practice and rich operational experience gained in more than 15 years of data platform construction. The new offering forms part of Lenovo’s comprehensive AI Services practice that provides training and tools to help customers maximize their use of AI.
Based on insights from the recent Lenovo CIO report, most organizations struggle with how to deploy AI-powered solutions quickly, effectively, and securely. To support customers globally, Lenovo announced a comprehensive AI services portfolio aligned with the Gartner® Five Critical AI Adoption Phases. The Lenovo AI CoE aims to accelerate these services and use cases to deliver faster outcomes and improve efficiency by harnessing AI to unlock the value of their data.
"With an experienced and expert team on hand, our collaboration with Databricks will accelerate AI readiness and move customers closer to responsible and efficient AI adoption,” added Art Hu, SVP & CIO for Lenovo, and Chief Technology and Delivery Officer for Lenovo’s Solutions and Services Group. "From architecture and data management, through to implementation and governance, we can provide end-to-end solutions that remove obstacles to AI integration and help customers get to the benefits at pace."
A relationship built on Lenovo’s own experience with the Databricks Platform
Lenovo’s work with Databricks builds on a relationship that started in 2022, with Lenovo creating its own enterprise-level global data warehouse through Databricks and fundamental Azure services. Incorporating corporate common data models and 200 core KPIs to date, the warehouse supports the breadth of the organization, from product and production to supply, sales and services.
With its experience in digital and intelligent transformation and now as an implementation partner for Databricks, Lenovo is able to provide data and AI solutions based on Lenovo’s Hybrid Cloud infrastructure. The Lenovo and Databricks collaboration means customers will benefit from a modern data platform with streamlined data governance to help them accelerate their enterprise reporting and analytics and the adoption of AI applications.
About Lenovo
Lenovo is a US$57 billion revenue global technology powerhouse, ranked #217 in the Fortune Global 500, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver Smarter Technology for All, Lenovo has built on its success as the world’s largest PC company with a pocket-to cloud portfolio of AI-enabled, AI-ready, and AI-optimized devices (PCs, workstations, smartphones, tablets), infrastructure (server, storage, edge, high performance computing and software defined infrastructure), software, solutions, and services. Lenovo’s continued investment in world-changing innovation is building a more equitable, trustworthy, and smarter future for everyone, everywhere. Lenovo is listed on the Hong Kong stock exchange under Lenovo Group Limited (HKSE: 992) (ADR: LNVGY). To find out more visit https://www.lenovo.com, and read about the latest news via our StoryHub.
LENOVO is a trademark of Lenovo. All other trademarks are the property of their respective owners. ©2024 Lenovo Group Limited.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240731568838/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
